The future diabetes treatment may lie in the monoclonal antibodies currently in R&D and clinical trials and stem cells. Mabs may shake up diabetes market
The progress of monoclonal antibodies through clinical trials and regulatory approval pathway may shake up the entire diabetes market and declining insulin sales. The 2 most advanced mabs ate Otelixizumab and Xoma 052 in Phase III trials in diabetes. This is despite Phase III failure of Teplizumab.